Adragos Pharma GmbH, a contract development and manufacturing organization (CDMO), acquired Lamda Laboratories S.A. in Athens.

With the transaction, Adragos Pharma will operate three sites in Europe and five globally. The acquisition of Lamda Laboratories significantly expands Adragos’ pharmaceutical product development, regulatory affairs, and supply chain management services for its global pharmaceutical customers.

Lamda will continue to provide services for Clinigen.

The Athens site is equipped with state-of-the-art equipment, which also allows the handling of highly potent pharmaceuticals, as well as established quality systems and a proven track record of delivering complex developments to customers on time. The official handover of the facility took place on April 3.

Andreas Raabe, CEO of Adragos Pharma said: “We are pleased to have carried out this acquisition. Lamda is of great importance to us because it extends our value chain coverage from pure manufacturing to development, allowing us to address a new customer group. At the same time, we can offer existing Lamda customers production capacity within the Adragos Group and existing Adragos Manufacturing customers a broader service offering.”